Erasca, Inc.

Healthcare

NASDAQ:ERAS · NASDAQ Global Select

Market Cap $4.37B Beta 0.73 P/E (TTM) -15.4

$14.05 +0.29%

+$0.04 today

52W Low $1.21High $24.28

Vol 2.08M · Avg 6.95M

EPS (TTM)-$0.91

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+849.32%

Period High

$22.47

Period Low

$1.26

Latest

$14.05

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

$1.46B

ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

$1.42B

MoonLake Immunotherapeutics

NASDAQ:MLTX

$1.38B

MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

$1.19B

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

$1.00B

MeiraGTx Holdings plc

NASDAQ:MGTX

$888.13M

Astria Therapeutics, Inc.

ATXS

$718.13M

Valneva SE

NASDAQ:VALN

$507.78M

Arvinas, Inc.

NASDAQ:ARVN

$489.07M

CytomX Therapeutics, Inc.

NASDAQ:CTMX

$484.08M

What is the latest ERAS filing?

The latest filing shown is SC 13G dated May 15, 2026.

How many recent filings does ERAS have?

Intrinsic Alpha currently shows 20 recent filings for ERAS.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.